oglobin levels have a higher rate of cardiovascular complications than patients who maintain a lower hemoglobin level. A similar effect of EPO on accelerating the decline of kidney function had been suggested by earlier studies. Our study suggests that caution may be warranted when maintaining higher hemoglobin concentration using exogenous EPO treatment in diabetic patients, as it might accelerate progression to PDR and ESRD."
Study co-author Dr. Dean Li, from the Program in Human Molecular Biology and Genetics at the University of Utah, added: "Though there is no proven pharmacologic treatment for diabetic vascular eye diseases, inhibiting the growth of unwanted blood vessel growth using antibodies directed against vascular endothelial growth factor [anti-VEGF therapy] has been advocated. This genetic study suggests that future therapeutic strategies need to consider blunting the effects of erythropoietin in addition, or as an alternative, to an anti-VEGF strategy."
More information
The U.S. National Eye Institute has more about diabetic eye disease.
-- Robert Preidt
SOURCE: University of Utah, news release, May 5, 2008
'/>"/>Copyright©2008 ScoutNews,LLC. All rights reserved | |
Page: 1 2 Related medicine news :1.
Gene Variant Boosts Risk for Stress-Related Ischemia 2.
Gene Variant Protects Black Heart Failure Patients3.
Gene Variants Linked to Lung Cancer Identified4.
Gene Variants Can Predict Threat of Heart Disease5.
Gene variant predicts medication response in patients with alcohol dependence6.
Gene variant linked to moderated symptoms of beta-thalassemia7.
Gene Variant Tied to More Aggressive Prostate Cancer8.
Gene Variant Doubles Risk of Prostate Cancer in Black Men9.
Scientists discover genetic variant associated with prostate cancer in African Americans10.
Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds11.
Obesity-Related Inflammation Boosts Heart Risks